玻璃体腔注射雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的效果评价

doi:10.6040/j.issn.1673-3770.0.2015.076

摘要/Abstract

摘要： 目的评价玻璃体腔注射雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的疗效及安全性。方法 2013年12月至2014年5月山东省立医院眼科收治新生血管性青光眼24例(24眼), 行玻璃体腔注射雷珠单抗联合小梁切除术及全视网膜光凝治疗, 比较手术前后患者视力、眼压, 观察术后并发症及手术成功率。结果随访8.6±1.7个月, 患者术后1周、1个月、3个月、6个月时的眼压分别为10.9±2.7 mmHg、13.3±3.2 mmHg、14.0±3.4 mmHg、15.4±5.1 mmHg, 与术前相比, 眼压均明显下降(P<0.01);患者应用抗青光眼药物数量分别为(0.2±0.5)种、(0.4±0.7)种、(0.4±0.8)种、(0.5±1.0)种, 与术前相比, 用药数量明显下降(P<0.01)。随访结束时, 14例患者视力稳定, 8例患者视力提高, 2例患者视力下降。术后6个月时的手术成功率为91.7%。结论玻璃体腔注射雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼安全、有效。

关键词: 小梁切除术, 全视网膜光凝, 新生血管性青光眼, 玻璃体腔注药, 雷珠单抗

Abstract: Objective To evaluate the efficacy and safety of intravitreal ranibizumab injection combined with trabelectomy and panretinal photocoagulation (PRP) in treatment of neovascular glaucoma. Methods Twenty-four patients (24 eyes) with neovascular glaucoma who underwent intravitreal ranibizumab injection combined with trabelectomy and PRP between December 2013 and May 2014 at Shandong Provicial Hospital were observed. During a follow-up period of 8.6±1.7 months, the pre-operative and post-operative visual acuity(VA), intraocular pressure (IOP) and number of anti-glaucoma medications, also the surgical complications and success rate were observed. Results Post-operative IOP was 10.9±2.7 mmHg, 13.3±3.2 mmHg, 14.0±3.4 mmHg and 15.4±5.1 mmHg at 1 week and 1, 3 and 6 months after the surgery, which was significantly decreased compared with pre-operative one(P<0.01). The number of anti -glaucoma medications was 0.2±0.5, 0.4±0.7, 0.4±0.8 and 0.5±1.0 at 1 week and 1, 3 and 6 months after the surgery, which was significantly decreased compared with the pre-treatment one(P<0.01). At the last visit, there were 14 eyes with stable VA, 8 with VA improvement, and 2 with diminished VA. Conclusion Intravitreal ranibizumab injection combined with trabelectomy and PRP is effective and safe for neovascular glaucoma.

Key words: Neovascular glaucoma, Ranibizumab, Intravitreal injection, Trabelectomy, Panretinal photocoagulation

中图分类号:

R775.3

柴雪荣, 张士玺, 陶钰, 申家泉. 玻璃体腔注射雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的效果评价[J]. 山东大学耳鼻喉眼学报, 2015, 29(3): 72-75.

CHAI Xuerong, ZHANG Shixi, TAO Yu, SHEN Jiaquan. Effect of intravitreal ranibizumab injection combined with trabelectomy and panretinal photocoagulation for neovascular glaucoma[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(3): 72-75.

参考文献

[1] Simha A, Braganza A, Abraham L, et al. Anti-vascular endothelial growth factor for neovascular glaucoma[J].Cochrane Database Syst Rev, 2013, 10:CD007920.doi:10.1002/14651858.CD007920.pub2.
[2] Brown D M, Michels M, Kaiser P K, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study[J]. Ophthalmology, 2009, 116(1):57-65.
[3] Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment:evidence from the RESTORE trial[J]. Br J Ophthalmol, 2012, 96(5):688-693.
[4] 申家泉, 王思聪.新生血管性青光眼研究进展[J].山东大学耳鼻喉眼学报, 2011, 5(5):92-93. SHEN Jiaquan, WANG Sicong. Research on neovascular glaucoma[J]. J Otolaryngol Ophthalmol Shandong Univ, 2011, 5(5):92-93.
[5] Shen C C, Salim S, Du H, et al. Trabeculectomy versus Ahmed Glaucoma Valve implantation in neovascular glaucoma[J]. Clin Ophthalmol, 2011, 5(2):281-286.
[6] Takihara Y, Inatani M, Fukushima M, et al. Trabeculectomy with mitomycin C for neovascular glaucoma:prognostic factors for surgical failure[J]. Am J Ophthalmol, 2009, 147(5):912-918.
[7] Netland P A, Ishida K, Boyle J W. The Ahmed Glaucoma Valve in patients with and without neovascular glaucoma[J].J Glaucoma, 2010, 19(9):581-586.
[8] Frezzotti P, Mittica V, Martone G, et al. Long term follow-up of diode laser transscleral cyclophotocoagulation in the treatment of refractory glaucoma[J].Acta Ophthalmol, 2010, 88(1):150-155.
[9] Izgi B, Demirci H, Demirci F Y, et al. Diode laser cyclophotocoagulation in refractory glaucoma: comparison between pediatric and adult glaucomas[J]. Ophthalmic Surg Lasers, 2000, 32(2):100-107.
[10] Schlote T, Derse M, Rassmann K, et al.Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma[J].J Glaucoma, 2001, 10(4):294-301.
[11] Alkawas A A, Shahien E A, Hussein A M. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C[J].J Glaucoma, 2010, 19(9):622-626.
[12] Saito Y, Higashide T, Takeda H, et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma[J]. Acta Ophthalmologica, 2010, 88(1):96-102.
[13] CATT Research Group, Martin D F, Maguire M G, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration[J]. N Engl J Med, 2011, 364(20):1897-1908.
[14] 王丽丽, 李立婕, 郑波, 等. Becacizumab联合格栅样光凝治疗CRVO黄斑水肿的临床观察[J]. 国际眼科杂志, 2011, 11(10):1769-1771. WANG Lili, LI Lijie, ZHENG Bo, et al. Clinical observation of Becacizumab combined with grid photocoagulation for the treatment of cystoid macular edema associated with central retinal vein occlusion[J].Inter J Ophthalmol, 2011, 11(10):1769-1771.
[15] Canut M I, Alvarez A, Nadal J, et al. Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma[J]. Clin Ophthalmol, 2011, 5:715.
[16] Zhang H T, Yang Y X, Xu Y Y, et al. Intravitreal bevacizumab and Ahmed glaucoma valve implantation in patients with neovascular glaucoma[J].Inter J Ophthalmol, 2014, 7(5):837-842.
[17] Miki A, Oshima Y, Otori Y, et al. One-year results of intravitreal bevacizumab as an adjunct to trabeculectomy for neovascular glaucoma in eyes with previous vitrectomy[J].Eye, 2011, 25(5):658-659.

相关文章 15

[1]	周学义,李一鸣,王美菊,张苑苑,张历浊. 25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 87-89.
[2]	许晓. Ex-PRESS引流器植入术治疗青光眼的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 90-93.
[3]	王越,柯敏,韩芳芳,王文欢,翁鸿. EX-PRESS引流器植入术与小梁切除术治疗开角型青光眼有效性和安全性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 104-111.
[4]	靳琳,潘庆敏,胡磊. 玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 96-98.
[5]	严槟,尹小芳,叶祖科,卢彦,洪剑威. 玻璃体腔注射雷珠单抗联合GLP治疗BRVO-ME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 110-113.
[6]	赵露,谢国丽,王艳玲. 玻璃体腔注射雷珠单抗对湿性年龄相关性黄斑变性患者眼血流动力学的影响[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 101-104.
[7]	龚斌, 范传峰, 王玉. 抗VEGF药物(雷珠单抗)治疗不同病程湿性年龄相关性黄斑变性62例[J]. 山东大学耳鼻喉眼学报, 2014, 28(5): 58-61.
[8]	韩萍, 许加凤, 胡凯. 小梁切除联合巩膜层间反折小梁组织垫入术治疗青光眼临床分析[J]. 山东大学耳鼻喉眼学报, 2014, 28(5): 74-75.
[9]	张奕霞，杨炜，邱明磊，陈宁宁. 重度Ⅱ型视盘血管炎的早期全光凝治疗[J]. 山东大学耳鼻喉眼学报, 2012, 26(4): 66-68.
[10]	徐红1，李明2，杨华3. 不同位置可调缝线在小梁切除联合丝裂霉素应用中的疗效比较[J]. 山东大学耳鼻喉眼学报, 2012, 26(3): 68-69.
[11]	李军，由新英. 原发性闭角型青光眼复合式小梁切除术后眼前节结构改变[J]. 山东大学耳鼻喉眼学报, 2010, 24(5): 64-66.
[12]	聂巧莉1，2，陶远2，吴欣怡1，郭百灵2. 小梁切除联合睫状体冷冻术与单纯睫状体冷冻术治疗绝对期新生血管性青光眼的效果比较[J]. 山东大学耳鼻喉眼学报, 2010, 24(4): 58-61.
[13]	王震,申家泉,张士玺. 小梁切除术联合MMC及生物羊膜移植可调整缝线治疗难治性青光眼的临床观察[J]. 山东大学耳鼻喉眼学报, 2009, 23(6): 67-70.
[14]	杨家干，李树杰，张莹. 球结膜、筋膜瓣错层缝合对青光眼小梁切除术后滤泡弥散程度的影响[J]. 山东大学耳鼻喉眼学报, 2009, 23(2): 94-97 .
[15]	刘真,于东珍,陈玮 . 小梁切除术中应用丝裂霉素C与术后应用肝素的对比研究[J]. 山东大学耳鼻喉眼学报, 2007, 21(3): 245-247 .

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed